Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nephros (NEPH) Cash & Equivalents (2016 - 2025)

Nephros (NEPH) has 16 years of Cash & Equivalents data on record, last reported at $5.2 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 110.46% year-over-year to $5.2 million; the TTM value through Sep 2025 reached $5.2 million, up 110.46%, while the annual FY2024 figure was $3.8 million, 12.7% down from the prior year.
  • Cash & Equivalents reached $5.2 million in Q3 2025 per NEPH's latest filing, up from $5.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $8.3 million in Q2 2021 and bottomed at $2.5 million in Q3 2024.
  • Average Cash & Equivalents over 5 years is $4.8 million, with a median of $4.2 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: crashed 49.52% in 2022, then soared 110.46% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $7.0 million in 2021, then tumbled by 47.88% to $3.6 million in 2022, then grew by 18.52% to $4.3 million in 2023, then dropped by 12.7% to $3.8 million in 2024, then skyrocketed by 37.53% to $5.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $5.2 million in Q3 2025, $5.1 million in Q2 2025, and $4.1 million in Q1 2025.